Name: Catalyst Pharmaceuticals, Inc. (CPRX) Financial Statements
Creator: FinSpry

Catalyst Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Catalyst Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	491.73	398.20	214.20	140.83	119.07	102.31	0.50
Cost of Revenue	68.85	51.97	54.18	38.82	17.04	14.76	0.00
Gross Profit	422.89	346.24	160.02	102.01	102.03	87.55	0.50
Operating Expenses
Research & Development	12.65	93.15	19.79	16.94	16.50	18.84	19.92
Selling, General & Administrative	177.74	133.71	57.09	49.63	44.23	36.88	15.88
Operating Expenses	227.77	226.86	58.18	49.63	60.73	55.72	35.80
Operating Income	195.12	86.81	101.84	52.39	41.30	31.82	-35.30
Other Income/Expense
Interest Income	16.06	4.68	0.00	0.28	0.59	0.00	1.29
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	21.14	-7.70	2.88	0.28	-0.59	-1.59	1.29
Income
Income Before Tax	216.26	94.51	104.72	52.67	41.89	33.41	-34.00
Income Tax Expense	52.37	23.10	21.64	13.19	-33.09	1.53	0.00
Net Income	163.89	71.41	83.08	39.48	74.98	31.88	-34.00
Net Income - Continuous Operations	163.89	71.41	83.08	39.48	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	232.90	127.39	103.08	52.58	41.40	33.46	-35.26
EBIT	216.26	94.51	101.84	52.39	41.30	33.41	-35.30
Depreciation & Amortization	37.77	32.88	1.24	0.19	0.09	0.00	0.00
Earnings Per Share
Basic EPS	1.00	1.00	1.00	-	1.00	-	-
Diluted EPS	1.00	1.00	1.00	-	1.00	-	-
Basic Shares Outstanding	118.46	106.28	103.37	103.38	103.51	102.94	102.63
Diluted Shares Outstanding	124.94	113.75	111.38	107.80	106.24	106.02	102.63